Roche Holding (RHHBY)
(Delayed Data from OTC)
$34.67 USD
-0.24 (-0.69%)
Updated Jun 28, 2024 03:59 PM ET
2-Buy of 5 2
C Value C Growth D Momentum C VGM
Roche Holding AG (RHHBY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$37.75 | $40.00 | $35.50 | 8.14% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Roche Holding AG comes to $37.75. The forecasts range from a low of $35.50 to a high of $40.00. The average price target represents an increase of 8.14% from the last closing price of $34.91.
Analyst Price Targets (2 )
Broker Rating
Roche Holding AG currently has an average brokerage recommendation (ABR) of 3.18 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 3.00 a month ago based on 12 recommendations.
Of the 11 recommendations deriving the current ABR, one is Strong Buy, representing 9.09% of all recommendations. A month ago, Strong Buy represented 16.67%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/RHHBY.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 2 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 8 | 8 | 8 | 7 | 7 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 3.18 | 3.18 | 3.00 | 3.20 | 3.20 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/30/2024 | Goldman Sachs | James Quigley | Not Available | Strong Sell |
5/20/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
5/6/2024 | UBS | Matthew Weston | Hold | Hold |
4/1/2024 | Cowen & Co. | Steve M Scala | Hold | Hold |
3/12/2024 | Not Identified | Not Identified | Hold | Hold |
3/5/2024 | Argus Research Corp. | Research Department | Not Available | Hold |
1/16/2024 | Not Identified | Not Identified | Hold | Hold |
9/5/2023 | Berenberg Bank | Luisa Hector | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.18 |
ABR (Last week) | 3.18 |
# of Recs in ABR | 11 |
Average Target Price | $37.75 |
LT Growth Rate | 1.80% |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 68 of 252 |
Current Quarter EPS Est: | NA |